Brooks Laboratories Limited
BROOKS.BO
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.07B
Close$
$-69.52
207.5% downside
Current Fair Value
207.5% downsideOvervalued by 207.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.07 Billion |
|---|---|
| Enterprise Value | $2.07 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $8.35 |
| Beta | 1.15 |
| Outstanding Shares | 29,457,248 |
Return
| Return on Equity | 10.77% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 15.62 |
|---|---|
| PEG | -13.16 |
| Price to Sales | 2.31 |
| Price to Book Ratio | 1.58 |
| Enterprise Value to Revenue | 2.48 |
| Enterprise Value to EBIT | 17.53 |
| Enterprise Value to Net Income | 15 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Brooks Laboratories Limited
347 employees
CEO: Prashant Rathi Established in 2002 and headquartered in Mumbai, India, Brooks Laboratories Limited operates as a pharmaceutical enterprise. The company focuses on the production and worldwide distribution of its medicinal offerings, serving both the In...